Receive our newsletter – data, insights and analysis delivered to you
June 8, 2009

Once-Weekly Exenatide Shows Encouraging Diabetes Results

Amylin, Eli Lilly and Alkermes have announced that a long-term study using exenatide, an investigational therapy for type 2 diabetes just once a week showed sustained glucose control with weight loss, as well as improvements in systolic blood pressure and triglycerides. The outcome was ob

By cms admin

Amylin, Eli Lilly and Alkermes have announced that a long-term study using exenatide, an investigational therapy for type 2 diabetes just once a week showed sustained glucose control with weight loss, as well as improvements in systolic blood pressure and triglycerides.

The outcome was observed during a duration-1 study over two years of treatment with exenatide once a week.

During the study, patients received exenatide once weekly or a Byetta (exenatide) injection for 30 weeks, followed by 74 weeks of treatment with exenatide once weekly for all patients.

The results showed that 65% of patients achieved an A1C level of 7% or less. Body weight was significantly reduced, with patients losing an average of 5.8lb. Serum lipid profiles were also significantly improved, and there was a significant reduction in systolic blood pressure.

Amylin senior vice president of research and development Orville Kolterman said that the two-year duration-1 data showed that maintenance of steady state concentrations of exenatide may result in sustained improvements in glycaemic control, with potential weight loss.”

“If approved, this therapy could fill an important unmet need for treating patients with type 2 diabetes with just one dose per week,” said Kolterman.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The companies have now submitted a New Drug Application for exenatide to the US Food and Drug Administration.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU